Cisplatin引起的聽力損失（CIHL）：市場展望、流行病學、競爭格局、市場預測報告，2025-2035年

市場概覽

• 德國市場預計將從約 70 萬美元成長到約 110 萬美元（年複合成長率約 4-5%）。
• 市場規模仍然很小，而且是一個小眾領域，但由於人們越來越關注預防性治療和倖存者護理（例如 STS），因此預計該領域將會成長。

Cisplatin誘發性聽力損失（CIHL）概述

Cisplatin誘導性聽力損失（CIHL）是一種高發生率、進行性且通常不可逆的雙側感音神經性聽力損失，是含鉑類藥物類化療的主要劑量限制性毒性。當Cisplatin在耳蝸內積聚並滯留時，會產生過量的活性氧（ROS），從而導致氧化壓力，進而引起關鍵聽覺結構（包括外毛細胞、螺旋神經節神經元和血管紋）的細胞凋亡。

臨床上，慢性特發性聽力損失（CIHL）初期表現為耳鳴和高頻率（4000-8000赫茲）聽力下降，逐漸擴展至言語頻率範圍，導致嚴重的溝通困難。其對兒童的影響尤其嚴重，可能導致語言發展和神經認知發展遲緩。對成人而言，CIHL 會顯著降低生活品質。

治療需要嚴格的聽力監測，包括在基準和整個化療過程中進行長時間的高頻聽力測試和耳聲傳射（OAE）檢查。傳統上，由於擔心會影響抗癌藥物的療效，預防策略受到限制。然而，近期的進展使得靜脈注射硫代硫酸鈉（STS）成為首個核准用於兒童病患的保護性藥物。在Cisplatin，可在維持腫瘤療效的同時降低耳毒性，這代表著癌症倖存者護理領域的重大進步。

主要亮點

• 化療引起的CIHL是一種常見的、不可逆的化療毒性，具有顯著的長期影響。
• 預計美國病例數將從約 378,000 例增加到約 398,000 例（年複合成長率約 0.5%）。

格式化和更新訊息

• 詳細報告（PDF）
• 市場預測模型（基於微軟Excel）
• 流行病學數據（MS Excel，互動式工具）
• 高階主管洞察（PPT簡報）
• 其他功能：定期更新、自訂和顧問支援。
• 根據 Thelansis 的政策，我們確保所有最新更新在發布前都反映在報告內容和市場模型中。

主要問題

• 我們如何最佳化 G8 市場（美國、歐盟 5 國、日本、中國）的藥物開發與生命週期管理策略？
• 從發病率、盛行率、人群組成以及接受藥物治療的患者人數來看，患者數量分別是多少？
• 未來十年市場收入和病患佔有率的預測是多少？
• 哪些因素對市場趨勢影響最大？
• 受訪專家對目前和新興的治療方法有何看法？
• 哪款在研發線產品最有前景？其上市潛力及未來市場定位如何？
• 主要未被滿足的需求是什麼？ KOL 對目標受眾有何期望？
• 為確保藥物核准並順利進入市場，必須滿足哪些關鍵的監管和支付方要求？

目標國家

• G8
  • 美國
  • EU5
    • 法國
    • 德國
    • 義大利
    • 西班牙
    • 英國
  • 日本
  • 中國

大公司

• Acousia Therapeutics
• Sensorion

目錄

第1章：主要調查結果及分析師說明

• 主要趨勢：市場概況、SWOT分析、商業性利益與風險等。

第2章：疾病背景

• 疾病定義、分類、病因和病理生理學、藥物標靶等。

第3章：流行病學

• 重點
• 發病率/盛行率
• 已確診並接受藥物治療的患者人數
• 合併症
• 其他相關患者群

第4章 市場規模及預測

• 重點
• 市場促進因素與限制因素
• 按藥物類別分類的趨勢
• 各國具體趨勢

第5章 競爭情勢

• 目前的治療方法
  • 重點
  • 診斷和治療過程/演算法
  • 主要治療方法概述及KOL洞察
• 新興治療方法
  • 重點
  • 值得關注的後期新治療方法－概述、市場上市預期及KOL洞察
  • 值得關注的早期管道

第6章：未滿足的需求與TPP分析

• 主要未滿足的需求以及透過新興治療方法實現的未來可能性
• TPP分析與KOL展望

第7章 監理與報銷環境

第8章附錄

Cisplatin-Induced Hearing Loss (CIHL) Market Outlook

Thelansis's "Cisplatin-Induced Hearing Loss (CIHL) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report - 2025 To 2035" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Cisplatin-Induced Hearing Loss treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Cisplatin-Induced Hearing Loss (CIHL) Overview

Cisplatin-induced hearing loss (CIHL) is a highly prevalent, progressive, and typically irreversible bilateral sensorineural hearing impairment, representing a major dose-limiting toxicity of platinum-based chemotherapy. The condition arises due to the accumulation and prolonged retention of cisplatin within the cochlea, where it generates excessive reactive oxygen species (ROS), leading to oxidative stress and apoptosis of critical auditory structures, including outer hair cells, spiral ganglion neurons, and the stria vascularis.

Clinically, CIHL initially presents with tinnitus and high-frequency hearing loss (4,000-8,000 Hz), which progressively extends into speech frequencies, resulting in significant communication impairment. The impact is particularly severe in pediatric populations, where it can lead to speech, developmental, and neurocognitive delays, while in adults it contributes to substantial quality-of-life deterioration.

Management requires rigorous audiological monitoring, including extended high-frequency audiometry and otoacoustic emissions (OAEs), conducted at baseline and throughout chemotherapy. Historically, preventive strategies were limited due to concerns of compromising anticancer efficacy. However, recent advances have introduced intravenous sodium thiosulfate (STS) as the first approved protective agent in pediatric patients, administered post-cisplatin infusion to mitigate ototoxicity while preserving tumor response, marking a significant advancement in survivorship care.

Key Highlights

• CIHL is a common, irreversible chemotherapy toxicity with significant long-term impact
• US incidence expected to increase from ~378K to ~398K (~0.5% CAGR)

Market Overview

• Germany market projected to grow from ~$0.7M to ~$1.1M (~4-5% CAGR)
• Market remains small and niche, with growth driven by protective therapies like STS and survivorship care focus

Insights driven by robust research, including:

• In-depth interviews with leading KOLs and payers
• Physician surveys
• RWE analysis for claims and EHR datasets
• Secondary research (e.g., peer-reviewed journal articles, third-party research databases)

Deliverables format and updates*:

• Detailed Report (PDF)
• Market Forecast Model (MS Excel-based automated dashboard)
• Epidemiology (MS Excel; interactive tool)
• Executive Insights (PowerPoint presentation)
• Others: regular updates, customizations, consultant support
• As per Thelansis's policy, we ensure that we include all the recent updates before releasing the report content and market model.

Salient features of Market Forecast model:

• 10-year market forecast (2025-2035)
• Bottom-up patient-based market forecasts validated through the top-down sales methodology
• Covers clinically and commercially-relevant patient populations/ line of therapies
• Annualized drug-level sales and patient share projections
• Utilizes our proprietary Epilansis and Analog tool (e.g., drug uptake and erosion) datasets and conjoint analysis approach
• Detailed methodology/sources & assumptions
• Graphical and tabular outputs
• Users can customize the model based on requirements

Key business questions answered:

• How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)?
• How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments?
• What is the 10-year market outlook for sales and patient share?
• Which events will have the greatest impact on the market's trajectory?
• What insights do interviewed experts provide on current and emerging treatments?
• Which pipeline products show the most promise, and what is their potential for launch and future positioning?
• What are the key unmet needs and KOL expectations for target profiles?
• What key regulatory and payer requirements must be met to secure drug approval and favorable market access?

Countries Covered

• G8
  • United States
  • EU5
    • France
    • Germany
    • Italy
    • Spain
    • U.K.
  • Japan
  • China

Apart from the G8 Market, adding any additional country data to the dashboard/report will cost USD 1,750 per country

Companies Mentioned

• Acousia Therapeutics
• Sensorion

Table of Contents

1. Key Findings and Analyst Commentary

• Key trends: market snapshots, SWOT analysis, commercial benefits and risks, etc.

2. Disease Context

• Disease definition, classification, etiology and pathophysiology, drug targets, etc.

3. Epidemiology

• Key takeaways
• Incidence / Prevalence
• Diagnosed and Drug-Treated populations
• Comorbidities
• Other relevant patient segments

4. Market Size and Forecast

• Key takeaways
• Market drivers and constraints
• Drug-class specific trends
• Country-specific trends

5. Competitive Landscape

• Current therapies
  • Key takeaways
  • Dx and Tx journey/algorithm
  • Key current therapies - profiles and KOL insights
• Emerging therapies
  • Key takeaways
  • Notable late-phase emerging therapies - profiles, launch expectations, KOL insights
  • Notable early-phase pipeline

6. Unmet Need and TPP Analysis

• Top unmet needs and future attainment by emerging therapies
• TPP analysis and KOL expectations

7. Regulatory and Reimbursement Environments (by country and payer insights)

8. Appendix (e.g., bibliography, methodology)